Literature DB >> 11713162

Pulmonary hypertension in patients with amyloidosis.

D Dingli1, J P Utz, M A Gertz.   

Abstract

Pulmonary hypertension (PH) with right-sided cardiac failure is a rare complication of amyloidosis, and its natural history is not well-defined. The aim of our study was to evaluate patients who were seen at our institution who had PH and amyloidosis and to describe the natural history of this complication. The study was a retrospective chart review of patients seen at the Mayo Clinic with both PH and amyloidosis listed as major diagnoses between January 1, 1980, and December 31, 1999. Patients with known causes of PH were excluded. Five patients met our criteria (four women and one man). Four patients had light-chain amyloidosis and one had amyloid A deposition secondary to familial Mediterranean fever. All patients had symptoms related to PH without echocardiographic evidence of left ventricular dysfunction. The median survival time after the diagnosis of amyloidosis was 2.8 years, and PH was found a median of 73 days before death. Five patients died of cardiac complications, including one with sudden cardiac death. PH is an unusual complication of amyloidosis. Patients develop PH late in the disease process and do not have a worse prognosis compared to other patients with cardiac amyloidosis. PH is a marker of advanced amyloidosis.

Entities:  

Mesh:

Year:  2001        PMID: 11713162     DOI: 10.1378/chest.120.5.1735

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  13 in total

1.  Severe reversible pulmonary hypertension in smoldering multiple myeloma: two cases and review of the literature.

Authors:  Wayne L Feyereisn; Eric R Fenstad; Robert B McCully; Martha Q Lacy
Journal:  Pulm Circ       Date:  2015-03       Impact factor: 3.017

Review 2.  Amyloid heart disease. New frontiers and insights in pathophysiology, diagnosis, and management.

Authors:  Walid Hassan; Hani Al-Sergani; Walid Mourad; Rashed Tabbaa
Journal:  Tex Heart Inst J       Date:  2005

3.  Current treatment in cardiac amyloidosis.

Authors:  Ivana Kholová; Josef Kautzner
Journal:  Curr Treat Options Cardiovasc Med       Date:  2006-12

4.  Pulmonary arterial hypertension in primary amyloidosis.

Authors:  Meghan M Cirulis; Lyska L Emerson; David A Bull; Nathan Hatton; Jose Nativi-Nicolai; Gerhard C Hildebrandt; John J Ryan
Journal:  Pulm Circ       Date:  2016-06       Impact factor: 3.017

5.  Pulmonary arterial hypertension due to pulmonary vascular amyloid deposition in a patient with multiple myeloma.

Authors:  Hirotsugu Hashimoto; Atsushi Kurata; Hideaki Mizuno; Tamaki Nashiro; Akira Hangaishi; Masahiko Kuroda; Kensuke Usuki; Hajime Horiuchi
Journal:  Int J Clin Exp Pathol       Date:  2015-11-01

Review 6.  Pulmonary hypertension and amyloidosis--an uncommon association: a case report and review of the literature.

Authors:  Lihi Eder; Devy Zisman; Raffael Wolf; Haim Bitterman
Journal:  J Gen Intern Med       Date:  2007-03       Impact factor: 5.128

7.  Autoimmune disease leading to pulmonary AL amyloidosis and pulmonary hypertension.

Authors:  Claire M Ellender; Catriona McLean; Trevor J Williams; Gregory I Snell; Helen M Whitford
Journal:  Respirol Case Rep       Date:  2015-05-21

8.  A Tale of Three Rarities: Secondary Amyloid A (AA) Amyloidosis Caused by Recurrent Sialadenitis and Complicated by Pulmonary Hypertension and Adrenal Insufficiency.

Authors:  Parth Desai; Chimezie Mbachi; Udit Joshi; Benjamin Mba
Journal:  Cureus       Date:  2020-04-23

9.  Pulmonary Vascular Disease Due to Plasma Cell Dyscrasia.

Authors:  Indranee Rajapreyar; Joanna Joly; Jose Tallaj; Salpy V Pamboukian; Ayman Haj Assad; Carrie Lenneman; Silvio Litovsky; Arka Chatterjee; Charles Hoopes; Andrew Lenneman
Journal:  Mayo Clin Proc Innov Qual Outcomes       Date:  2020-11-20

Review 10.  Cardiac manifestations of Familial Mediterranean fever.

Authors:  Ahmad Alsarah; Osama Alsara; Heather S Laird-Fick
Journal:  Avicenna J Med       Date:  2017 Oct-Dec
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.